We also found that high levels of DSG2, LDHA, and RACGAP1 predicted poorer overall (Supplementary Fig. S4B) and disease-free survival in pancreatic cancer patients (Supplementary Fig. S4C), although these three genes did not all show good performance in the four validation datasets (Supplementary Fig. S5A–D). This evidence concerns the gene DSG2 and familial pancreatic carcinoma.